A Phase 3 interventional study of cabozantinib and mitoxantrone in Prostate Cancer, Castration Resistant Prostate Cancer and Pain, sponsored by Exelixis. Terminated at 82 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-23.
Sponsored by Exelixis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing cabozantinib in Prostatic Neoplasms — 3 open to participants now, 6 under way, 2 of them phase 3. cabozantinib · Prostatic Neoplasms.
Among the 23 studies testing cabozantinib in Prostatic Neoplasms, this one is the 6th largest by enrollment, is one of 6 that started in 2012, is one of 4 in phase 3, and was the 3rd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →3 of the 23 studies testing cabozantinib in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+ · Men only
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+
Exelixis · Sites in United States
By country, each count listing its studies:
cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cabozantinib is the treatment under test here. Read study by study →
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 4
First in 2009; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 33 across the 23 interventional studies. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 23 have an industry lead sponsor. The 10 most frequent:
Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Exelixis has 7 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing cabozantinib in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05168618University of UtahCabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | 2026-11 |
| NCT05613894University of UtahDose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing cabozantinib in Prostatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bone metastases and associated pain are a major cause of morbidity and mortality in castration-resistant prostate cancer (CRPC). Most approved therapies have shown some ability to reduce soft tissue lesions but none meaningfully impacts bone metastases (as demonstrated by lack of resolution of lesions on bone scan with these agents) or the pain associated with these metastases.
This study will evaluate the effect of cabozantinib versus mitoxantrone plus prednisone on pain response and bone scan response in men with CRPC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to the cabozantinib arm will also receive placebo mitoxantrone injections (color-matched with methylene blue) and placebo prednisone capsules. There will be a maximum of 10 infusions for mitoxantrone placebo.
Drug: cabozantinib
Subjects randomized to the mitoxantrone + prednisone arm will also receive placebo cabozantinib tablets. There will be a maximum of 10 infusions for mitoxantrone.
Drug: mitoxantrone · Drug: prednisone
Tablets taken orally once daily.
Given by IV once every 3 weeks.
Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
Pain Response at Week 6 Confirmed at Week 12, Week 12 Reported
The pre-specified primary analysis of Pain Response at Week 6 confirmed at Week 12 was defined as ≥ 30% from baseline in the average daily worst pain intensity score during a 7-day reporting period, with neither a concomitant increase in average daily use of any opioid narcotic type, nor addition of any new opioid narcotic type, relative to baseline. Pain Progression at a given time point is defined as ≥ 30% increase compared with baseline in the average daily worst pain intensity score during a 7-day reporting period or either an increase in the average daily use of any type of opioid narcotic or addition of a new opioid narcotic type compared with baseline.
Time frame: Pain response was measured at Week 6 and Week 12 by self-reports of subjects
Bone Scan Response (BSR)
BSR is defined as \>=30% in the bone scan lesion area (BSLA) compared with baseline. Bones scans were evaluated by an independent radiology facility (IRF) for response.
Time frame: BSR was measured at the end of Week 12 as determined by the IRF
Overall Survival (OS)
OS was defined as the time from randomization to the date of death (due to any cause). Participants that had not died were censored at last known date alive. The analyses for OS occurred after 78/196 deaths (40% of the total required for the pre-specified primary analysis of OS). The data cut-off date was 06 October 2014. Median OS was calculated using Kaplan-Meier estimates.
Time frame: OS was measured at the time of randomization until 78 deaths
First patient enrolled: 15 March 2012, Data cut off date: 06 October 2014. The study was terminated by the Sponsor after 119 subjects were enrolled which was less than the planned sample size of 246 subjects.
| Milestone | Cabozantinib | Mitoxantrone/Prednisone |
|---|---|---|
| Started | 61 | 58 |
| Completed | 8 | 3 |
| Not completed | 53 | 55 |
| Withdrew: No longer receiving clinical benefit | 36 | 28 |
| Withdrew: Adverse event | 10 | 15 |
| Withdrew: Withdrawal by subject | 5 | 8 |
| Withdrew: No study treatment given | 1 | 1 |
| Withdrew: Other | 1 | 3 |
The pre-specified primary analysis of Pain Response at Week 6 confirmed at Week 12 was defined as ≥ 30% from baseline in the average daily worst pain intensity score during a 7-day reporting period, with neither a concomitant increase in average daily use of any opioid narcotic type, nor addition of any new opioid narcotic type, relative to baseline. Pain Progression at a given time point is defined as ≥ 30% increase compared with baseline in the average daily worst pain intensity score during a 7-day reporting period or either an increase in the average daily use of any type of opioid narcotic or addition of a new opioid narcotic type compared with baseline.
| percentage of responders | Cabozantinib | Mitoxantrone/Prednisone |
|---|---|---|
| Pain Response at Week 6 Confirmed at Week 12, Week 12 Reported | 15 (5.9 to 24) | 17 (7.5 to 27) |
BSR is defined as \>=30% in the bone scan lesion area (BSLA) compared with baseline. Bones scans were evaluated by an independent radiology facility (IRF) for response.
| percentage of responders | Cabozantinib | Mitoxantrone/Prednisone |
|---|---|---|
| Bone Scan Response (BSR) | 31 (20 to 43) | 5.2 (0 to 11) |
OS was defined as the time from randomization to the date of death (due to any cause). Participants that had not died were censored at last known date alive. The analyses for OS occurred after 78/196 deaths (40% of the total required for the pre-specified primary analysis of OS). The data cut-off date was 06 October 2014. Median OS was calculated using Kaplan-Meier estimates.
| months | Cabozantinib | Mitoxantrone/Prednisone |
|---|---|---|
| Overall Survival (OS) | 9.0 (6.80 to 11.56) | 7.9 (5.26 to 9.10) |
Collected over Up to 95 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cabozantinib | — | 16/60 (26.7%) | 60/60 (100%) |
| Mitoxantrone/Prednisone | — | 15/57 (26.3%) | 57/57 (100%) |
| Event | Cabozantinib | Mitoxantrone/Prednisone |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/60 | 4/57 |
| NeutropeniaBlood and lymphatic system disorders | 0/60 | 3/57 |
| Abdominal painGastrointestinal disorders | 0/60 | 2/57 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/60 | 2/57 |
| NauseaGastrointestinal disorders | 2/60 | 1/57 |
| PneumoniaInfections and infestations | 2/60 | 1/57 |
| DiarrhoeaGastrointestinal disorders | 1/60 | 1/57 |
| VomitingGastrointestinal disorders | 1/60 | 1/57 |
| AstheniaGeneral disorders | 1/60 | 1/57 |
| PyrexiaGeneral disorders | 1/60 | 1/57 |
| Event | Cabozantinib | Mitoxantrone/Prednisone |
|---|---|---|
| NauseaGastrointestinal disorders | 38/60 | 24/57 |
| FatigueGeneral disorders | 34/60 | 27/57 |
| Decreased appetiteMetabolism and nutrition disorders | 28/60 | 23/57 |
| DiarrhoeaGastrointestinal disorders | 27/60 | 17/57 |
| Weight decreasedInvestigations | 25/60 | 8/57 |
| ConstipationGastrointestinal disorders | 24/60 | 19/57 |
| VomitingGastrointestinal disorders | 23/60 | 19/57 |
| HypertensionVascular disorders | 18/60 | 0/57 |
| AstheniaGeneral disorders | 14/60 | 4/57 |
| DepressionPsychiatric disorders | 14/60 | 8/57 |
| Age, Customized(participants) | Cabozantinib | Mitoxantrone/Prednisone | Total |
|---|---|---|---|
| <65 years | 24 | 26 | 50 |
| 65 to <75 years | 30 | 26 | 56 |
| 75 to <85 years | 7 | 6 | 13 |
| Sex: Female, Male(Participants) | Cabozantinib | Mitoxantrone/Prednisone | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 61 | 58 | 119 |
| Ethnicity (NIH/OMB)(Participants) | Cabozantinib | Mitoxantrone/Prednisone | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 57 | 57 | 114 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Race/Ethnicity, Customized(participants) | Cabozantinib | Mitoxantrone/Prednisone | Total |
|---|---|---|---|
| American Indian/Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 3 | 4 |
| Black/African-American | 8 | 3 | 11 |
| Multiple | 1 | 0 | 1 |
| White | 49 | 51 | 100 |
| Not Reported | 0 | 1 | 1 |
| Other | 1 | 0 | 1 |
| Geographic Region(participants) | Cabozantinib | Mitoxantrone/Prednisone | Total |
|---|---|---|---|
| North America | 44 | 36 | 80 |
| Europe | 8 | 13 | 21 |
| Asia | 9 | 9 | 18 |
| ECOG Performance Status (per IVRS/IWRS)(participants) | Cabozantinib | Mitoxantrone/Prednisone | Total |
|---|---|---|---|
| 0-1 (normal to symptoms, but ambulatory) | 53 | 52 | 105 |
| ≥2 (ambulatory to incapable of self-care/death) | 8 | 6 | 14 |
| Randomization Stratification Factors (per IVRS/IWRS)(participants) | Cabozantinib | Mitoxantrone/Prednisone | Total |
|---|---|---|---|
| ECOG = 0-1 and prior cabazitaxel: yes | 18 | 18 | 36 |
| ECOG = 0-1 and prior cabazitaxel: no | 35 | 34 | 69 |
| ECOG ≥ 2 and prior cabazitaxel: yes | 7 | 6 | 13 |
| ECOG ≥ 2 and prior cabazitaxel: no | 1 | 0 | 1 |
| Time from initial diagnosis to randomization(years) | Cabozantinib | Mitoxantrone/Prednisone | Total |
|---|---|---|---|
| Median | 4.7 (0 to 18) | 5.3 (0 to 16) | 5.0 (0 to 18) |
8 further baseline measures are reported on the registry.
The record gives a start of Mar 2012, a primary completion of Oct 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2018, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabozantinib